Dasatinib has shown superiority over imatinib in achieving molecular responses (MRs) in chronic phase chronic myeloid leukemia but with a different toxicity profile, which may impact its overall benefit. Reported toxicities include pleural effusions and pulmonary hypertension, and although the incidence of these events is well described, response to therapy and impact of dose modifications on toxicity has not been comprehensively characterized in a real-world setting. We retrospectively reviewed the incidence of dasatinib adverse events in 212 chronic phase chronic myeloid leukemia patients at 17 Australian institutions. Adverse events were reported in 116 patients (55%), most commonly pleural effusions (53 patients, 25%), which was the predominant cause of permanent drug cessation. Age and dose were risk factors for pleural effusion (P < .01 and .047, respectively). Recurrence rates were higher in those who remained on 100 mg compared with those who dose reduced (P = .041); however, recurrence still occurred at 50 mg. Patients who developed pleural effusions were more likely to have achieved MR4.5 after 6 months of dasatinib than those without effusions (P = .008). Pulmonary hypertension occurred in 5% of patients, frequently in association with pleural effusion, and was reversible upon dasatinib cessation in 6 of 7 patients. Dose reductions and temporary cessations had minimal impact on MR rates. Our observations suggest that by using the lowest effective dose in older patients to minimize the effusion risk, dose modification for cytopenias, and care with concomitant antiplatelet therapy, the necessity for permanent dasatinib cessation due to toxicity is likely to be minimal in immunologically competent patients.
Background: The BCL2 family of proteins induce apoptosis via caspase activation and are being increasingly targeted in hematologic malignancies by small molecules such as venetoclax (VEN). However, BCL2-selective inhibition can often lead to drug resistance mediated by upregulation of anti-apoptotic proteins such as BCLxl. To broaden therapeutic activity, we developed AZD0466, a drug-dendrimer conjugate in which the BCL-2/xL dual inhibitor AZD4320 is covalently conjugated to a pegylated poly-L-lysine dendrimer and gradually released by hydrolysis. Preclinically, AZD4320 showed activity in patient (pt)-derived AML xenografts and superior tumor growth inhibition to VEN and navitoclax in VEN-resistant xenograft models (Balachander et al. Clin Cancer Res 2020). Aims: To report preliminary data from an ongoing Phase 1/2 dose escalation and expansion study, NIMBLE - drug deNdrIMer targeting BCL2/xL in acute LEukemias (NCT04865419) - designed to evaluate preliminary safety and tolerability (primary objectives), and pharmacokinetics (PK) and preliminary efficacy (secondary objectives). Methods: Module 1, Part A dose escalation evaluated target doses of 300–3600mg, with escalation/de-escalation per a mTPI-2 design. AZD0466 is administered intravenously with a ramp-up on d1, d4, d8 in cycle 1, reaching target dose on d8, and weekly administrations thereafter. Duration of cycle 1 is 35 days; subsequent cycles are 28 days. Module 2 investigates drug-drug interactions between AZD0466 and voriconazole. Pts remain on study until progressive disease, withdrawal of consent, or unacceptable toxicity. Eligible pts are ≥18 years old with relapsed/refractory (R/R) acute leukemia without active CNS disease, or with intermediate- or high-risk myelodysplastic syndrome. We report results from Module 1, part A. Results: As of 24 Jan 2023, 24 pts (n=20 AML, n=4 ALL; median age 69.5 yrs; ECOG 1–2 in 67% of pts) had received ≥1 dose of AZD0466 (300mg, n=4; 600mg, n=4; 1200mg, n=7; 2400mg, n=4; 3600mg, n=5). Median treatment duration was 4.1 (0.9–8) weeks. No dose-limiting toxicities (DLTs) were observed in the DLT-evaluable population (n=19). Any-grade AZD0466-related adverse events (AEs) were reported for 50% of pts (n=12), with related AEs grade ≥3 in 25% (n=6) of pts and any AE leading to discontinuation in 1 pt. The most common related any-grade AEs were aspartate aminotransferase (n=5, 21%) and alanine aminotransferase level elevations (n=4, 17%), followed by febrile neutropenia (n=3, 13%) and diarrhea (n=2, 8%). Serious AZD0466-related AEs were reported in one pt (4%). One AE of intracranial bleeding deemed not related to AZD0466 was reported. As a marker of BCLxL on-target activity, transient worsening of thrombocytopenia post-dose, with rapid platelet recovery prior to the next dose, was observed. This was in line with preclinical modeling showing a decrease in platelets post-dose compared to pre-dose starting at lower doses (300/600mg), with a ceiling effect after 1200mg and little further reduction at higher doses. Among pts with ≥1 follow-up bone marrow (BM) assessment available, preliminary anti-leukemia activity based on BM blast reduction at 1200 and 2400mg was observed in 2 pts. Based on clinical and PK data, and comparison of exposures observed in the clinic and predicted from preclinical murine models, further dose escalation to 5400mg is planned to evaluate safety and clinical efficacy. Enrollment is ongoing. Summary/Conclusion: Treatment with AZD0466 is well tolerated in pts with R/R acute leukemia, with AEs matching expected toxicity from preclinical data. Preclinical efficacy modeling and clinical PK data suggest further dose escalation is warranted to explore clinical activity. Keywords: BCL-XL, ALL, BCL2, Acute myeloid leukemia
The safety and efficacy of sabatolimab, a novel immunotherapy targeting T-cell immunoglobulin domain and mucin domain-3 (TIM-3), was assessed in combination with hypomethylating agents (HMAs) in patients with HMA-naive revised International Prognostic System Score (IPSS-R) high- or very high-risk myelodysplastic syndromes (HR/vHR-MDS) or chronic myelomonocytic leukemia (CMML). Sabatolimab + HMA had a safety profile similar to that reported for HMA alone and demonstrated durable clinical responses in patients with HR/vHR-MDS. These results support the ongoing evaluation of sabatolimab-based combination therapy in MDS, CMML, and acute myeloid leukemia. To the Editor: Patients with higher-risk myelodysplastic syndromes/neoplasms (MDS) and chronic myelomonocytic leukemia (CMML) have poor prognoses and need novel therapies that produce durable responses with sustained clinical benefit.1-4 Initial therapy for higher-risk MDS usually includes a hypomethylating agent (HMA), either azacitidine or decitabine,5 but benefits are modest, with <20% of patients achieving complete remission (CR) and a median duration of any response <15 months.6, 7 Patients with CMML treated with HMAs8 also have poor outcomes.9 T-cell immunoglobulin domain and mucin domain-3 (TIM-3)10 are expressed on immune cells and myeloid leukemic cells, and function as an inhibitory surface receptor regulating innate and adaptive immune responses, as well as promoting leukemic stem cell (LSC) self-renewal through interaction with galectin-9.11-15 Increased TIM-3 expression on leukemic progenitors has been described at the time of leukemic progression, suggesting the TIM-3 pathway may be involved in disease transformation to acute myeloid leukemia (AML).16, 17 Conditional knockout of TIM-3 on dendritic cells (DCs) promotes strong antitumor immunity.18 Sabatolimab, a novel monoclonal antibody targeting TIM-3, may interact with the dysregulated immune microenvironment in MDS, and directly with TIM-3-expressing leukemic progenitors.11, 19, 20 Early studies indicate the pharmacokinetic and safety profile of sabatolimab monotherapy is favorable for combination with standard of care therapies in the management of patients with myeloid malignancies.21-23 This Phase Ib trial of sabatolimab + HMA was conducted to evaluate safety, response rate by revised International Working Group (IWG) criteria, and durability of response in patients with high- or very high-risk MDS (HR/vHR-MDS) or CMML.24 This was a Phase Ib, multi-arm, open-label, multicenter study of sabatolimab for patients with AML, HR-/vHR-MDS, or CMML (NCT03066648). This study is focused on the sabatolimab + HMA combination in patients with HR-/vHR-MDS or CMML (Table S1 and Figure S1). The primary objective was to evaluate the safety/tolerability of this combination. Secondary objectives included efficacy, immunogenicity, and effect on modulation of immune cell markers in blood and paired bone marrow samples.33 Further details on the design and methodology of the study are provided in Appendix S1. The study was conducted in accordance with ICH Harmonized Tripartite Guidelines for Good Clinical Practice and the Declaration of Helsinki; written informed consent was obtained from each patient. Between July 6, 2017 and February 15, 2021, 53 patients with HR/vHR-MDS (HR-MDS, n = 32; vHR-MDS, n = 21) and 15 patients with CMML were enrolled. At the September 6, 2021 data cutoff, 34 and 19 patients had received sabatolimab in combination with azacitidine or decitabine, respectively. Baseline characteristics for patients with HR/vHR-MDS or CMML are reported in Table S2. At data cutoff, treatment in patients with HR/vHR-MDS was ongoing in nine patients (17.0%; Table S3). The most common reasons for treatment discontinuation were progressive disease (PD, 30.2%) or allogeneic transplantation (24.5%). Disposition data for patients with CMML are in Table S4. Sabatolimab dose selection and presence of anti-drug antibodies are described in Appendix S1. In patients with HR/vHR-MDS, common adverse events (AEs; all grades, regardless of relationship to study drug) were constipation (56.6% of patients), thrombocytopenia (56.6%), nausea (54.7%), neutropenia (47.2%), and anemia (45.3%) (Table S5 and Figure S2). Serious AEs were reported in 31 patients (58.5%; Table S5). Seven patients with HR/vHR-MDS had possible immune-mediated AEs (imAEs; time to onset, 18–481 days; Table S6 and Appendix S1). Sabatolimab dose interruption occurred in 21 (40%) patients (Table S5). AEs leading to sabatolimab discontinuation were reported in one patient (1.9%): a 75-year-old man with neutropenic colitis suspected to be related to study treatment discontinued treatment and died of septic shock. No other treatment-related deaths were reported. Possible imAEs leading to treatment interruption were reported in two patients (43.8%). Treatment-related AEs and possible imAEs are reported in Tables S7 and S8. The safety profile in patients with CMML treated with sabatolimab + HMA was consistent with those with HR/vHR-MDS (Figure S3 and Table S9). Safety data for a cohort of patients (n = 8) on sabatolimab monotherapy are in Tables S10 and S11. Among 51 evaluable patients with HR/vHR-MDS, overall response rate (ORR) was 56.9% (95% confidence interval [CI], 42.2%–70.7%); 19.6% of patients achieved CR, 23.5% achieved bone marrow CR (mCR; 11.8% of all evaluable patients achieved mCR + hematologic improvement [HI]), 3.9% achieved partial response (PR), and 9.8% achieved stable disease (SD) with HI (Figure 1A). The median time to response (TTR) was 2.0 months (range, 1.7–9.6). Among patients who achieved CR, mCR, or PR, the median duration of response (mDOR) was 17.1 months (95% CI, 6.7–not estimable [NE]; Figure 1A,B); mDOR among patients who achieved CR was 19.3 months (95% CI, 12.1–NE). The mDOR among patients who achieved mCR with HI was 7.9 months (95% CI, 3.0–NE) and not estimable among patients who achieved mCR without HI and PR. Twenty patients experienced events considered progression and 33 patients were censored for progression-free survival (PFS), 20 of whom started new lines of therapy (which was considered a censoring event for PFS), including transplant. Median PFS was 17.2 months (95% CI, 6.6–23.3); the estimated 12-month PFS rate was 54.0% (95% CI, 33.0%–71.0%) (Figure 1A,C). Efficacy data in patients with HR/vHR-MDS treated with sabatolimab monotherapy are reported in Table S13. The impact of blast burden, TP53 and other ELN 2017 adverse-risk mutations,25 and imAEs on treatment response are described in Appendix S1. Among 15 evaluable patients with CMML, ORR was 66.7% (95% CI, 38.4%–88.2%) and mDOR was 5.6 months (95% CI, 3.0–NE; Table S12). Post-study outcome analyses on overall survival (OS) and responses in patients who proceeded to allogeneic hematopoietic cell transplantation are described in Appendix S1. Across the entire cohort, the median OS was 26.7 months. Of the 19 patients who underwent allogeneic transplant, the post-transplant survival rate at 2 years was 69%. Currently approved therapies for treating higher-risk MDS and CMML are palliative; complete responses to treatment are infrequent, and responses are generally short-lived.8, 26 In this Phase Ib study, sabatolimab did not add clinically important toxicity to standard-of-care HMA treatment in patients with HR/vHR-MDS or CMML, resulting in few sabatolimab dose interruptions and very rare discontinuations, suggesting that the combination has the potential to yield more durable responses without additional safety concerns. A challenge in treating patients with MDS or CMML is that many patients are elderly and may harbor comorbid conditions that preclude intensive treatment options.8, 27, 28 AEs observed with sabatolimab + HMA were consistent with those previously reported for HMA alone. Randomized studies are underway to better characterize any added toxicity from combination therapy.29 Possible imAEs were specifically examined because sabatolimab inhibits TIM-3, which is an inhibitory immune receptor; these AEs are thought to be secondary to the disruption of immunologic self-tolerance.30 Few patients had clinically significant possible imAEs, with no grade ≥ 3 events reported. Interestingly, all seven patients with possible imAEs achieved a response, although only ~25% of responders experienced possible imAEs. This observed relationship between response and possible imAEs needs further confirmation. Because of concerns related to exposure to immunological therapies around transplant, we also assessed patients who received sabatolimab and subsequently proceeded to allogeneic transplant, noting generally favorable survival given the high-risk disease in this cohort and usual transplant risks; few of these patients experienced severe graft versus host disease. Further data will be important to assess the safety of transplant after sabatolimab exposure. OS with this combination compared with HMA alone is being evaluated in ongoing STIMULUS trials (NCT03946670 and NCT04266301). Duration of clinical responses in patients with HR/vHR-MDS was encouraging compared with historical data, with an mDOR of 17.1 months compared with 10–15 months with HMA alone.6, 7 These longer responses were also observed in patients with adverse-risk mutations (mDOR 21.5 months). The duration of responses observed with sabatolimab + HMA in the overall (17.1 months) and TP53-mutated patient (21.5 months) populations is encouraging, although confirmation in larger randomized studies with longer follow-up is needed. These findings are consistent with a putative immunomodulatory component to the mechanism of action for sabatolimab. Based on this study and others,23, 31 doses of 400 mg every 2 weeks (Q2W) and 800 mg every 4 weeks (Q4W) were selected for further evaluation. The 800 mg Q4W dosing regimen of sabatolimab was then established based on pharmacokinetics/pharmacodynamics analysis, convenience of dosing, and lack of differences in toxicity or responses.21 Limitations of this Phase Ib study are the non-randomized open-label design, absence of HMA-alone control arms, and heterogeneity of the patient population. In the subsequent STIMULUS-MDS1 study (NCT03946670), CR and PFS were not statistically different between patients with intermediate-risk (IR)/HR/vHR-MDS given sabatolimab + HMA versus HMA alone. Considering the potential of a delayed-onset benefit and that OS is more indicative of the effect of an immunomodulatory therapy compared with short-term CR, the study is still ongoing to collect long-term safety and survival data,32 and the STIMULUS-MDS-2 study (NCT04266301), which has a primary OS endpoint, has completed enrollment. In conclusion, sabatolimab could be combined with standard HMA therapy in patients with HR/vHR-MDS or CMML, including patients with adverse-risk mutations, with safety comparable to HMA monotherapy and early signals of extended duration of responses. We identified a dose of sabatolimab (800 mg Q4W) in combination with HMA for future studies. The results underscore the potential of TIM-3 as a therapeutic target in myeloid malignancies and support ongoing exploration of sabatolimab treatment in various combination regimens. All authors contributed equally to the writing of the manuscript and read and approved the final manuscript. Medical writing support was provided by Bridget Sackey-Aboagye, PhD, of Healthcare Consultancy Group, and was funded by Novartis Pharmaceuticals Corporation. Andrew M. Brunner has received consulting fees from Acceleron, Agios, BMS/Celgene, Gilead, Keros Therapeutics, Novartis, Takeda, and Taiho. His research is supported by the Edward P. Evans Foundation and NIH NCI. Jordi Esteve has received consulting fees from Abbvie, Novartis, Astellas, Jazz Pharmaceuticals, BMS-Celgene, Pfizer, Amgen, and Daichii-Sankyo; and research grants to his institution and cooperative group CETLAM from Novartis, Pfizer, and Jazz Pharmaceuticals. Kimmo Porkka has received honoraria from AbbVie, Astellas Pharma, BMS/Celgene, Incyte, Novartis, and Pfizer; and has received research funding to his institution from AbbVie BMS/Celgene, Incyte, Novartis, and Pfizer. Steve Knapper reports consultancy and speakers bureau participation for Pfizer, Astellas, Jazz, and Novartis; and research funding from Novartis. Elie Traer serves on ad boards for Astellas, AbbVie, Servier, Daiichi-Sankyo, Rigel; and receives research funding from Incyte, Schrodinger, Prelude Therapeutics, and AstraZeneca. Sebastian Scholl reports research funding from Novartis; advisory boards for Novartis, Pfizer, and Amgen. Guillermo Garcia-Manero has nothing to disclose. Norbert Vey has nothing to disclose. Martin Wermke reports consultancy, research funding, and honoraria from Novartis, Roche, Pfizer, and BMS. Jeroen J. W. M. Janssen reports research support from Novartis and BMS to institution; he is president of the Apps for Care and Science, a nonprofit foundation that develops the HematologyApp and is supported by AbbVie, Alexion, Amgen, Astellas, Astra Zeneca, BMS, Daiichi-Sankyo, Janssen-Cilag, Olympus, Incyte, Sanofi Genzyme, Servier, Jazz, Takeda; honoraria for advisory boards from AbbVie, Novartis, Pfizer, and Incyte to institution. Rupa Narayan reports Novartis research funding to institution. Shaun Fleming has nothing to disclose. Sun Loo has nothing to disclose. Natalia Tovar has nothing to disclose. Mika Kontro reports consultancy for Astellas Pharma; research funding from AbbVie; and membership on an entity's Board of Directors or advisory committees for AbbVie, Astellas Pharma, BMS/Celgene, and Jazz Pharmaceuticals. Oliver G. Ottmann has received honoraria from Incyte, Novartis, Amgen and Celgene, and has received research funding to his institution from Incyte, Roche, and Celgene. Purushotham Naidu reports employment with Novartis. Haiying Sun HS reports employment with Novartis and is a Novartis stockholder. May Han has nothing to disclose. Roisin White reports employment with Novartis. Na Zhang reports employment with Novartis before when NZ was working on this project. Anisa Mohammed reports employment with Novartis and is a Novartis stockholder. Catherine A. Sabatos-Peyton was an employee of Novartis and holds patents on TIM-3 through BWH/Harvard and CoStim.Novartis. CAS-P is employed by and has options in Larkspur Biosciences. David P. Steensma reports employment with Novartis when working on this project. Mikael L. Rinne reports prior employment with Novartis and consultancy for Qiagen; reports current employment with Blueprint Medicines and is a Blueprint Medicines stockholder. Uma M. Borate reports Consulting for Kura Oncology. Andrew H. Wei has served on advisory boards for Novartis, Janssen, Amgen, Roche, Pfizer, AbbVie, Servier, Celgene-BMS, MacroGenics, Agios, and Gilead; receives research funding to the institution from Novartis, AbbVie, Servier, Celgene-BMS, AstraZeneca, and Amgen; serves on speakers bureaus for AbbVie, Novartis, and Celgene; receives royalty payments from the Walter and Eliza Hall Institute of Medical Research related to venetoclax. Novartis will not provide access to patient-level data, if there is a reasonable likelihood that individual patients could be re-identified. Phase I studies, by their nature, present a high risk of patient re-identification; therefore, patient individual results for Phase I studies cannot be shared. In addition, clinical data, in some cases, have been collected subject to contractual or consent provisions that prohibit transfer to third parties. Such restrictions may preclude granting access under these provisions. Where co-development agreements or other legal restrictions prevent companies from sharing particular data, companies will work with qualified requestors to provide summary information where possible. DATA S1. Supporting Information. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Revumenib, an oral, small molecule inhibitor of the menin-lysine methyltransferase 2A (KMT2A) interaction, showed promising efficacy and safety in a phase I study of heavily pretreated patients with
Measurable residual disease (MRD) is being recognised as an optimal method for assessing depth of response, identifying higher risk of relapse, and guiding response-based treatment paradigms for multiple myeloma (MM). Although MRD negativity is increasingly replacing complete response as the surrogate endpoint in clinical trials, its role in real-world practice is less established. We retrospectively analyzed EuroFlow MRD results from patients with newly diagnosed MM (NDMM) who underwent bortezomib, cyclophosphamide and dexamethasone (VCD) induction and high dose melphalan conditioned autologous stem cell transplant (ASCT) at the Alfred Hospital between January 2016 and December 2020. Next generation flow MRD evaluation was performed 3 months following ASCT using the standardised EuroFlow platform. 112 patients with available MRD data were identified to have received VCD induction followed by ASCT. Post ASCT MRD was undetectable in 28.6% of patients. Those who achieved MRD negativity had significantly longer progression free survival (PFS) than those with persisting MRD (24-month PFS of 85% [95% CI: 72.4-99.9%] vs 63% [95% CI: 52.9-75.3%], p = 0.022). Maintenance therapy was associated with improved PFS regardless of MRD status (24-month PFS of 100% [95% CI: NA, p = 0.02] vs 73% [95% CI: 53.1-99.6%] in MRD negative, and 75% [95% CI: 64.2-88.6%] vs 36% [95% CI: 20.9-63.2%, p = 0.00015] in MRD positive patients). Results from this retrospective study of real-world practice demonstrate that Euroflow MRD analysis following standard VCD induction and ASCT in NDMM is feasible and allows more accurate prognostication, providing a platform for response adaptive therapies.
PURPOSE The B-cell lymphoma 2 (BCL-2) inhibitor venetoclax has an emerging role in acute myeloid leukemia (AML), with promising response rates in combination with hypomethylating agents or low-dose cytarabine in older patients. The tolerability and efficacy of venetoclax in combination with intensive chemotherapy in AML is unknown. PATIENTS AND METHODS Patients with AML who were ≥ 65 years (≥ 60 years if monosomal karyotype) and fit for intensive chemotherapy were allocated to venetoclax dose-escalation cohorts (range, 50-600 mg). Venetoclax was administered orally for 14 days each cycle. During induction, a 7-day prephase/dose ramp-up (days −6 to 0) was followed by an additional 7 days of venetoclax combined with infusional cytarabine 100 mg/m 2 on days 1-5 and idarubicin 12 mg/m 2 intravenously on days 2-3 (ie, 5 + 2). Consolidation (4 cycles) included 14 days of venetoclax (days −6 to 7) combined with cytarabine (days 1-2) and idarubicin (day 1). Maintenance venetoclax was permitted (7 cycles). The primary objective was to assess the optimal dose schedule of venetoclax with 5 + 2. RESULTS Fifty-one patients with a median age of 72 years (range, 63-80 years) were included. The maximum tolerated dose was not reached with venetoclax 600 mg/day. The main grade ≥ 3 nonhematologic toxicities during induction were febrile neutropenia (55%) and sepsis (35%). In contrast to induction, platelet recovery was notably delayed during consolidation cycles. The overall response rate (complete remission [CR]/CR with incomplete count recovery) was 72%; it was 97% in de novo AML and was 43% in secondary AML. During the venetoclax prephase, marrow blast reductions (≥ 50%) were noted in NPM1-, IDH2-, and SRSF2-mutant AML. CONCLUSION Venetoclax combined with 5 + 2 induction chemotherapy was safe and tolerable in fit older patients with AML. Although the optimal postremission therapy remains to be determined, the high remission rate in de novo AML warrants additional investigation (ANZ Clinical Trial Registry No. ACTRN12616000445471).
Background: The advent of pediatric inspired regimens has improved the outcome for younger adults with Acute Lymphoblastic Leukaemia (ALL), however this comes at a considerable toxicity burden limiting its applicability in older adults. The Australasian Leukaemia and Lymphoma Group (ALLG) undertook a phase 2 proof-of-concept (POC) study of Blinatumomab with RI chemotherapy in adults with newly diagnosed (newDx) Ph neg BCP-ALL. Aims: To assess response, the effectiveness and tolerability of the combination of Blinatumomab with RI chemotherapy following a debulking steroids and chemotherapy for newDx Ph- B-ALL in older adults. Methods: The ALLG ALL8 study (ACTRN12617000084381) is a phase II POC study for patients fit for treatment with a Hyper-CVAD-like regimen (between 40-65 years) with newly diagnosed Ph neg B-lineage ALL. Patients with CNS involvement were excluded. A steroid pre-phase (Prednisolone 100mg daily for 7 days) was followed by a disease debulking phase of cyclophosphamide 150mg/m2 BD day 1-3, vincristine 2mg day 1 & 11 and dexamethasone 10mg/m2 day 1-4 and 11-14. Patients then received alternating cycles of Blinatumomab (at 9mcg/d for the first 7 days of cycle 1 followed by 28mcg/d until day 28) with B-cycles of Hyper-CVAD (Methotrexate 1g/m2 day 1, Cytarabine 3g/m2 BD day 2,3, Methylprednisolone 50mg BD day 1-3) (figure 1) for a total of 4 cycles. All received intrathecal prophylaxis with methotrexate, cytarabine and hydrocortisone prior to blinatumomab treatment blocks and day 1 and 8 of each B-cycle, total of 8 doses. High-risk patients (MLL translocations, hypodiploid, complex karyotype or MRD positive at TP3) were recommended for allogeneic stem cell transplant while others continued to receive 24 months of POMP maintenance. Minimal residual disease testing was performed at a centralised EuroMRD accredited laboratory. MRD positivity was defined as a detectable level of ≥ 1 x 10-4. This is the analysis of the final endpoint as at 14th February 2023. POC criteria were defined on an observed event free rate of ≥ 63%. Results: 30 subjects were enrolled (21 (70%) Male), with a median age of 51.7 years (39.5 – 66.5 years) with 14 (47%) ECOG 0, 12 (40%) ECOG 1, and 4 (13%) ECOG 2 at time of study entry. 5 (17%) subjects had high-risk cytogenetics. 100% of subjects attained composite CR (CR/CRi) with 28 (93%) attaining this by the end of 1B, and a further 2 by the end of cycle 2B. MRD response was ≤10-4 in 19/27 (70%) of subjects at the end of 1B and 20/24 (83%) of subjects at the end of 2B. The estimated EFS at 24 months was 60.4% (median EFS 36.1 mo) with OS at 24 months of 78.6% (median OS NR). This was insufficient to meet the pre-specified proof-of-concept criteria. The regimen was well tolerated with the major toxicity being infective (53 episodes of infection). There were 2 episodes of cytokine release syndrome (1 grade 3), and 7 episodes of grade 3 neurological toxicity (1 myelopathy and 4 neuropathy related to chemotherapy and 2 episodes of neurotoxicity related to blinatumomab). 4 patients proceeded to alloHSCT. Summary/Conclusion: Blinatumomab with chemotherapy was well tolerated with a high rate of remission and deep MRD responses in the majority of patients. Responses appeared durable with this lower intensity treatment approach despite a low rate of allogeneic stem cell transplantation and the exclusion of anthracyclines and asparaginase from treatment. Despite failing to meet proof-of-concept criteria the EFS and OS were encouraging for older ALL patients and demonstrates the feasibility of combining low-intensity chemotherapy with blinatumomab in older adults with BCP-ALL.Keywords: B cell acute lymphoblastic leukemia, Acute lymphoblastic leukemia
'/%3e%3c/defs%3e%3cpath fill='%23012169' d='M0 0h10080v5040H0z'/%3e%3cpath stroke='%23fff' stroke-width='.6' d='m0 0 6 3m0-3L0 3' clip-path='url(%23b)' transform='scale(840)'/%3e%3cpath stroke='%23e4002b' stroke-width='.4' d='m0 0 6 3m0-3L0 3' clip-path='url(%23c)' transform='scale(840)'/%3e%3cpath stroke='%23fff' stroke-width='840' d='M2520 0v2520M0 1260h5040'/%3e%3cpath stroke='%23e4002b' stroke-width='504' d='M2520 0v2520M0 1260h5040'/%3e%3cg fill='%23fff'%3e%3cuse xlink:href='%23d' x='2520' y='3780'/%3e%3cuse xlink:href='%23a' x='7560' y='4200'/%3e%3cuse xlink:href='%23a' x='6300' y='2205'/%3e%3cuse xlink:href='%23a' x='7560' y='840'/%3e%3cuse xlink:href='%23a' x='8680' y='1869'/%3e%3cuse xlink:href='%23e' x='8064' y='2730'/%3e%3c/g%3e%3c/svg%3e)